After four years of inactivity, the US Food and Drug Administration (FDA) approved three novel products for hereditary ...

Annual Meeting 2025, findings from a Phase II clinical trial of NA-931 were presented. The study evaluated the weight-loss ...

The letter issuances are part of President Trump’s order to stamp out drug advertisements that fall short of regulatory ...

Vinay Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER), has also been particularly outspoken ...

At EASD 2025, investigators reported that miR‑155 is upregulated within the pancreas of donors with T1D and in ...

Annual Meeting 2025, findings were shown from the Phase IIIa REDEFINE 2 trial, assessing Novo Nordisk’s fixed-dose ...

At ESAD 2025, researchers reported that Viperin (RSAD2) is strongly induced by inflammatory cytokines in pancreatic beta cells and islets.

China’s Mabwell Bioscience and US-based Aditum Bio have launched Kalexo Bio, a new company, to develop new siRNA candidate, ...

At the 2025 European Association for the Study of Diabetes (EASD) meeting in Vienna, SAB Biotherapeutics presented Phase 1 ...

At EASD 2025, investigators reported one-year outcomes from a study of zimislecel (VX-880), an allogeneic, stem cell-derived ...

Merging high-potency and green chemistry expertise, Indena and TCG GreenChem are setting new global standards in ...

The API and drug product facility is the first of four new manufacturing plants set to be built by Eli Lilly in the US over ...